| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 3, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)
S-3 - Elicio Therapeutics, Inc. (0001601485) (Filer)
10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapyThe induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized anti-tumor response BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival ("DFS"); event-driven primary DFS analysis now anticipated in 1H 2026.Since the beginning of Q3 2025, the Company has raised gross proceeds of approximately $11.1 million through its established at-the-market program, exten
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and in other senior leadership roles at multiple publicly traded biotechnology companies. "We are pleased to welcome Preetam to Elicio's executive team," said Robert Connelly, Ph.D., Preside
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics. Ms. Filoon will oversee all company legal affairs including corporate governance and compliance functions. Dr. Kheoh will provide biostatistical leadership and strategic guidance into the development of the Company's product candidate portfolio including the ongoing AMPLIFY-201 and AMPLIFY-7P trials of the lead asset, ELI-002. "Megan and Thian are joining us at an exc
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)
SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)